Equillium to Participate in the 38th Annual Roth Conference
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on March 23, 2026 at 8:30am PT.
Rhea-AI Summary
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on March 23, 2026 at 8:30am PT. The company said members of management will also be available for investor meetings with conference registrants.
This presentation offers investors direct access to management and updates on corporate strategy and development plans.
Positive
- None.
Negative
- None.
Details
News Market Reaction – EQ
On Mar 18, the day this news came out, EQ closed 0.93% below the previous close.
Data tracked by StockTitan Argus for the Mar 18 session.
Key Figures
- Conference edition
- 38th
- 38th Annual Roth Conference for Growth Companies
- Conference date
- March 23, 2026
- Scheduled fireside chat date
- Session time
- 8:30am PT
- Time of Equillium fireside chat
Historical Context
-
Announced approximately $35M PIPE financing with RA Capital to extend cash runway.
-
Planned fireside chat and investor meetings at Leerink Partners healthcare conference.
-
Reported stock option inducement grants to new employees under 2024 Inducement Plan.
-
Planned participation in December 2025 Piper Sandler and Evercore ISI healthcare conferences.
-
Q3 2025 results plus private placement of up to $50M and EQ504 development plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
autoimmune medical
inflammatory disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT.
Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
About Equillium
Equillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
For more information, visit www.equilliumbio.com.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.